Agency Forms Undergoing Paperwork Reduction Act Review, 23297-23299 [2016-09190]
Download as PDF
Federal Register / Vol. 81, No. 76 / Wednesday, April 20, 2016 / Notices
the agreement, and revise the minimum
level of service to be provided by the
agreement.
Agreement No.: 011953–013.
Title: Florida Shipowners Group
Agreement.
Parties: The member lines of the
Caribbean Shipowners Association and
the Florida–Bahamas Shipowners and
Operators Association.
Filing Party: Wayne Rohde, Esq.;
Cozen O’Connor; 1200 Nineteenth Street
NW.; Washington, DC 20036.
Synopsis: The amendment updates
Appendix A to update the membership
of the Caribbean Shipowners
Association.
Agreement No.: 012282–001.
Title: Kyowa Shipping Co., Ltd. and
Nippon Yusen Kaisha Space Charter
Agreement.
Parties: Kyowa Shipping Co., Ltd. and
Nippon Yusen Kaisha.
Filing Party: Kristen Chung, Corporate
Counsel, NYK Line (North America)
Inc.; 300 Lighting Way, 5th Floor;
Secaucus, NJ 07094.
Synopsis: The amendment adds the
trade between American Samoa and
Japan to the geographic scope of the
agreement.
Agreement No.: 012399.
Title: NYK/Zim Slot Exchange
Agreement.
Parties: Nippon Yusen Kaisha and
Zim Integrated Shipping Services Co.,
Ltd.
Filing Party: Mark E. Newcomb; ZIM
American Integrated Shipping Services,
Co. LLC; 5801 Lake Wright Dr.; Norfolk,
VA 23508.
Synopsis: The agreement authorizes
the parties to charter slots on each
other’s vessels in the trade between the
U.S. on the one hand, and China,
Vietnam, Singapore, Malaysia,
Thailand, Sri Lanka, Egypt, Italy, United
Arab Emirates, and Canada on the other
hand.
By Order of the Federal Maritime
Commission.
Dated: April 15, 2016.
Karen V. Gregory,
Secretary.
Board of Governors of the Federal Reserve
System, April 15, 2016.
Margaret McCloskey Shanks,
Deputy Secretary of the Board.
[FR Doc. 2016–09146 Filed 4–19–16; 8:45 am]
BILLING CODE 6731–AA–P
[FR Doc. 2016–09124 Filed 4–19–16; 8:45 am]
FEDERAL RESERVE SYSTEM
Lhorne on DSK5TPTVN1PROD with NOTICES
CFR 225.41) to acquire shares of a bank
or bank holding company. The factors
that are considered in acting on the
notices are set forth in paragraph 7 of
the Act (12 U.S.C. 1817(j)(7)).
The notices are available for
immediate inspection at the Federal
Reserve Bank indicated. The notices
also will be available for inspection at
the offices of the Board of Governors.
Interested persons may express their
views in writing to the Reserve Bank
indicated for that notice or to the offices
of the Board of Governors. Comments
must be received not later than May 5,
2016.
A. Federal Reserve Bank of Atlanta
(Chapelle Davis, Assistant Vice
President) 1000 Peachtree Street, NE.,
Atlanta, Georgia 30309. Comments can
also be sent electronically to
Applications.Comments@atl.frb.org:
1. William Stuart Perry, Howard
Steven Perry, William Cavanagh Perry,
Constance Ann Perry Thomas, Carrie
Peighton Perry VanAusdall, and
Edmond Lewis Perry, all of Nashville,
Georgia, Sara Amelia Perry Parkerson,
Greensboro, Georgia, and Justin Stuart
Perry, Hilton Head, South Carolina; to
retain voting shares of The Nashville
Holding Company, and thereby
indirectly retain voting shares of The
Citizens Bank, both in Nashville,
Georgia.
B. Federal Reserve Bank of
Minneapolis (Jacquelyn K. Brunmeier,
Assistant Vice President) 90 Hennepin
Avenue, Minneapolis, Minnesota
55480–0291:
1. Dean M. Wehri, as a trustee/
administrator of the Commercial Bank
of Mott Employee Stock Ownership
Plan and Trust, both of Mott, North
Dakota; to acquire voting shares of
Commercial Bank of Mott Employee
Stock Ownership Plan and Trust, and
thereby indirectly acquire voting shares
of Commercial Bank of Mott, both in
Mott, North Dakota.
BILLING CODE 6210–01–P
Change in Bank Control Notices;
Acquisitions of Shares of a Bank or
Bank Holding Company
14:53 Apr 19, 2016
Jkt 238001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day–16–1067]
Agency Forms Undergoing Paperwork
Reduction Act Review
The Centers for Disease Control and
Prevention (CDC) has submitted the
following information collection request
to the Office of Management and Budget
(OMB) for review and approval in
accordance with the Paperwork
Reduction Act of 1995. The notice for
the proposed information collection is
published to obtain comments from the
public and affected agencies.
Written comments and suggestions
from the public and affected agencies
concerning the proposed collection of
information are encouraged. Your
comments should address any of the
following: (a) Evaluate whether the
proposed collection of information is
necessary for the proper performance of
the functions of the agency, including
whether the information will have
practical utility; (b) Evaluate the
accuracy of the agencies estimate of the
burden of the proposed collection of
information, including the validity of
the methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected; (d) Minimize the burden of
the collection of information on those
who are to respond, including through
the use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and (e) Assess information
collection costs.
To request additional information on
the proposed projects or to obtain a
copy of the information collection plan
and instruments, call (404) 639–7570 or
send an email to omb@cdc.gov. Direct
written comments and/or suggestions
regarding the items contained in this
notice to the Attention: CDC Desk
Officer, Office of Management and
Budget, Washington, DC 20503 or by fax
to (202) 395–5806. Written comments
should be received within 30 days of
this notice.
Proposed Project
Improving the Impact of Laboratory
Practice Guidelines (LPGs): A New
Paradigm for Metrics—College of
American Pathologists (OMB Control
No. 0920–1067)—Revision—Center for
Surveillance, Epidemiology and
The notificants listed below have
applied under the Change in Bank
Control Act (12 U.S.C. 1817(j)) and
§ 225.41 of the Board’s Regulation Y (12
VerDate Sep<11>2014
23297
PO 00000
Frm 00029
Fmt 4703
Sfmt 4703
E:\FR\FM\20APN1.SGM
20APN1
23298
Federal Register / Vol. 81, No. 76 / Wednesday, April 20, 2016 / Notices
Laboratory Services (CSELS), Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
The Centers for Disease Control and
Prevention (CDC) funded the College of
American Pathologists (CAP) as one of
three professional organizations in 5year cooperative agreement projects
collectively entitled ‘‘Improving the
Impact of Laboratory Practice
Guidelines: A New Paradigm for
Metrics.’’ An ‘‘LPG’’ is defined as
written recommendations for voluntary,
standardized approaches for medical
laboratory testing that takes into account
processes for test selection, sample
procurement and processing, analytical
methods, and results reporting for
effective diagnosis and management of
disease and health conditions. The
overall purpose of these cooperative
agreements is to increase the
effectiveness of LPGs by defining
measures and collecting information to
inform better LPG creation, revision,
dissemination, promotion, uptake, and
impact on clinical testing and public
health. The project will explore how
these processes and their impediments
and facilitators differ among various
intended users of LPGs. Through this
demonstration project, CDC seeks to
understand how to customize LPG
creation and promotion to better serve
these intended users of LPGs. An
important goal is to help organizations
that sponsor the development of LPGs
create a sustainable approach for
continuous quality improvement to
evaluate and improve an LPG’s impact
through better collection of information.
One of the awardees is the College of
American Pathologists (CAP). This
revision request concerns additional
information collection relating to the
CAP’s LPG for immunohistochemistry
(IHC) testing, for which a post
dissemination survey was approved
under OMB Control No. 0920–1067 and
has been completed. We are requesting
a revision to the OMB-approved 0920–
1067 package by adding two
information collections: Telephone
interviews and focus groups as a follow-
up to the completed IHC LPG post
survey to further explore the survey
findings that are being analyzed now.
The questions to be used for the
telephone interviews and focus groups
are based on the questions and results
of the IHC post survey, to help CAP and
CDC better understand the impediments
and facilitators that affect uptake of the
IHC LPG. The intended participants in
the proposed telephone interviews and
focus groups will be selected from the
IHC post survey respondents which
include pathologists, pathology chairs,
clinical laboratory directors, laboratory
managers overseeing the IHC staining
department, laboratory supervisors, and
histotechnologists.
This revision request represents a
decrease in burden. The proposed
telephone interviews will explore the
impediments and facilitators that affect
uptake and use of the CAP IHC LPG,
both generally and concerning specific
recommendations. This will be followed
by two focus groups, arranged into two
peer groups of pathologists (composed
of pathologists, pathology chairs, and
laboratory directors) and nonpathologist laboratory professionals
(composed of laboratory managers,
laboratory supervisors, and
histotechnologists for the purpose of
estimating burden), which will allow us
to collect information on the current
usage of CAP’s tools and resources
(toolkit) to facilitate implementation of
the IHC guideline for its future
improvement.
For this request, the CAP will collect
information via 40 telephone interviews
(20 pathologists, 10 laboratory directors,
and 10 laboratory managers). The
telephone interview questions are
scripted to be completed within 20
minutes by each respondent (0.33 hour
per respondent or ∼13 hours total).
Because the CAP anticipates that
approximately 121 laboratory
individuals (41 pathologists, 40
laboratory directors, and 40 laboratory
managers) will need to be contacted to
reach 40 individuals who will
voluntarily participate, and the burden
for those individuals who will not go on
to participate (81) in the telephone
interview is one minute, the total
burden for individuals who decline
participation is 81 minutes (1.35 hours).
In addition, the CAP will conduct two
focus group sessions and invite 12
participants to each of the sessions,
composed of the following respondent
types: (4) Pathologists, (4) pathology
chairs, (4) laboratory directors, (4)
laboratory managers, (4) laboratory
supervisors, and (4) histotechnologists.
Each of the focus groups will last no
more than 60 minutes (1.0 hour) which
is based on standard focus group
planning instructions, inclusive of time
required to complete informed consent
(24 hours or 1,440 minutes total
burden). It is anticipated that 200
individuals will be contacted to
determine their availability to
participate in one of the two focus group
sessions and each will take no longer
than 5 minutes to read and respond to
the invitation letter (∼17 hours or 1000
minutes total). The 200 individuals
contacted will be composed of the
following respondent types: (34)
Pathologists, (33) pathology chairs, (33)
laboratory directors, (34) laboratory
managers, (33) laboratory supervisors,
and (33) histotechnologists.
This revision includes three types of
laboratory professionals who were not
included in the original OMB-approved
submission: Pathology chairs, laboratory
supervisors, and histotechnologists.
Because the OMB-approved IHC postsurvey has been completed, this request
for approval of additional data
collection (telephone interviews and
focus groups) is a reduction of burden.
The total new burden for this revision
request will be ∼58 hours which is a
reduction of 1,512 hours from the
previously approved submission. A total
of 321 respondents (121 invited to take
the telephone interview and 200 invited
to participate in focus groups), is a
reduction of 4,114 respondents with an
approved burden of 1,570 hours and
4,435 respondents).
There are no costs to respondents
other than their time.
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Lhorne on DSK5TPTVN1PROD with NOTICES
Form name
Type of respondent
IHC telephone interview-contacted .................
Pathologists ....................................................
Laboratory Directors .......................................
Laboratory Managers .....................................
Pathologists ....................................................
Laboratory Directors .......................................
Laboratory Managers .....................................
Pathologists ....................................................
IHC telephone interview ..................................
IHC focus group invitation ..............................
VerDate Sep<11>2014
14:53 Apr 19, 2016
Jkt 238001
PO 00000
Frm 00030
Fmt 4703
Sfmt 4703
E:\FR\FM\20APN1.SGM
41
40
40
20
10
10
34
20APN1
Number of
responses per
respondent
Average
burden per
response
(in hours)
1
1/60
1
20/60
1
5/60
23299
Federal Register / Vol. 81, No. 76 / Wednesday, April 20, 2016 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS—Continued
Number of
respondents
Form name
Type of respondent
IHC focus group ..............................................
Pathology Chairs ............................................
Laboratory Directors .......................................
Laboratory Managers .....................................
Laboratory Supervisors ..................................
Histotechnologists ..........................................
Pathologists ....................................................
Pathology Chairs ............................................
Laboratory Directors .......................................
Laboratory Managers .....................................
Laboratory Supervisors ..................................
Histotechnologists ..........................................
LeRoy A. Richardson,
Chief, Information Collection Review Office,
Office of Scientific Integrity, Office of the
Associate Director for Science, Office of the
Director, Centers for Disease Control and
Prevention.
[FR Doc. 2016–09190 Filed 4–19–16; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket No. CDC–2015–0089]
Final Revised Vaccine Information
Materials for 9-valent HPV (Human
Papillomavirus) Vaccine
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice.
AGENCY:
Under the National
Childhood Vaccine Injury Act
(NCVIA)(42 U.S.C. 300aa–26), CDC must
develop vaccine information materials
that all health care providers are
required to give to patients/parents prior
to administration of specific vaccines.
On October 22, 2015, CDC published a
notice in the Federal Register (80 FR
64002) seeking public comments on
proposed updated vaccine information
materials for 9-valent HPV (Human
Papillomavirus) Gardasil®-9 vaccine.
Following review of comments
submitted and consultation as required
under the law, CDC has finalized the
materials. Copies of the final vaccine
information materials for 9-valent HPV
Gardasil®-9 vaccine are available to
download from https://www.cdc.gov/
vaccines/hcp/vis/ or https://
www.regulations.gov (see Docket
Number CDC–2015–0089).
DATES: Beginning no later than July 1,
2016, each health care provider who
Lhorne on DSK5TPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
14:53 Apr 19, 2016
Jkt 238001
administers 9-valent HPV (Human
Papillomavirus) Gardasil®-9 vaccine to
any child or adult in the United States
shall provide copies of the relevant
vaccine information materials
referenced in this notice, in
conformance with the March 31, 2016
CDC Instructions for the Use of Vaccine
Information Statements prior to
providing such vaccinations.
FOR FURTHER INFORMATION CONTACT:
Suzanne Johnson-DeLeon (msj1@
cdc.gov), National Center for
Immunization and Respiratory Diseases,
Centers for Disease Control and
Prevention, Mailstop A–19, 1600 Clifton
Road NE., Atlanta, Georgia 30329.
SUPPLEMENTARY INFORMATION: The
National Childhood Vaccine Injury Act
of 1986 (Pub. L. 99–660), as amended by
section 708 of Public Law 103–183,
added section 2126 to the Public Health
Service Act. Section 2126, codified at 42
U.S.C. 300aa–26, requires the Secretary
of Health and Human Services to
develop and disseminate vaccine
information materials for distribution by
all health care providers in the United
States to any patient (or to the parent or
legal representative in the case of a
child) receiving vaccines covered under
the National Vaccine Injury
Compensation Program (VICP).
Development and revision of the
vaccine information materials, also
known as Vaccine Information
Statements (VIS), have been delegated
by the Secretary to the Centers for
Disease Control and Prevention (CDC).
Section 2126 requires that the materials
be developed, or revised, after notice to
the public, with a 60-day comment
period, and in consultation with the
Advisory Commission on Childhood
Vaccines, appropriate health care
provider and parent organizations, and
the Food and Drug Administration. The
law also requires that the information
contained in the materials be based on
available data and information, be
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
33
33
34
33
33
4
4
4
4
4
4
Number of
responses per
respondent
1
Average
burden per
response
(in hours)
1
presented in understandable terms, and
include:
(1) A concise description of the
benefits of the vaccine,
(2) A concise description of the risks
associated with the vaccine,
(3) A statement of the availability of
the National Vaccine Injury
Compensation Program, and
(4) Such other relevant information as
may be determined by the Secretary.
The vaccines initially covered under
the National Vaccine Injury
Compensation Program were diphtheria,
tetanus, pertussis, measles, mumps,
rubella, and poliomyelitis vaccines.
Since April 15, 1992, any health care
provider in the United States who
intends to administer one of these
covered vaccines is required to provide
copies of the relevant vaccine
information materials prior to
administration of any of these vaccines.
Since then, the following vaccines have
been added to the National Vaccine
Injury Compensation Program, requiring
use of vaccine information materials for
them as well: Hepatitis B, Haemophilus
influenzae type b (Hib), varicella
(chickenpox), pneumococcal conjugate,
rotavirus, hepatitis A, meningococcal,
human papillomavirus (HPV), and
seasonal influenza vaccines.
Instructions for use of the vaccine
information materials are found on the
CDC Web site at: https://www.cdc.gov/
vaccines/hcp/vis/.
Revised Vaccine Information Materials
The 9-valent HPV (Human
Papillomavirus) Gardasil®-9 vaccine
information materials referenced in this
notice were developed in consultation
with the Advisory Commission on
Childhood Vaccines, the Food and Drug
Administration, and parent and
healthcare provider organizations.
Following consultation and review of
comments submitted, the vaccine
information materials covering 9-valent
E:\FR\FM\20APN1.SGM
20APN1
Agencies
[Federal Register Volume 81, Number 76 (Wednesday, April 20, 2016)]
[Notices]
[Pages 23297-23299]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-09190]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30Day-16-1067]
Agency Forms Undergoing Paperwork Reduction Act Review
The Centers for Disease Control and Prevention (CDC) has submitted
the following information collection request to the Office of
Management and Budget (OMB) for review and approval in accordance with
the Paperwork Reduction Act of 1995. The notice for the proposed
information collection is published to obtain comments from the public
and affected agencies.
Written comments and suggestions from the public and affected
agencies concerning the proposed collection of information are
encouraged. Your comments should address any of the following: (a)
Evaluate whether the proposed collection of information is necessary
for the proper performance of the functions of the agency, including
whether the information will have practical utility; (b) Evaluate the
accuracy of the agencies estimate of the burden of the proposed
collection of information, including the validity of the methodology
and assumptions used; (c) Enhance the quality, utility, and clarity of
the information to be collected; (d) Minimize the burden of the
collection of information on those who are to respond, including
through the use of appropriate automated, electronic, mechanical, or
other technological collection techniques or other forms of information
technology, e.g., permitting electronic submission of responses; and
(e) Assess information collection costs.
To request additional information on the proposed projects or to
obtain a copy of the information collection plan and instruments, call
(404) 639-7570 or send an email to omb@cdc.gov. Direct written comments
and/or suggestions regarding the items contained in this notice to the
Attention: CDC Desk Officer, Office of Management and Budget,
Washington, DC 20503 or by fax to (202) 395-5806. Written comments
should be received within 30 days of this notice.
Proposed Project
Improving the Impact of Laboratory Practice Guidelines (LPGs): A
New Paradigm for Metrics--College of American Pathologists (OMB Control
No. 0920-1067)--Revision--Center for Surveillance, Epidemiology and
[[Page 23298]]
Laboratory Services (CSELS), Centers for Disease Control and Prevention
(CDC).
Background and Brief Description
The Centers for Disease Control and Prevention (CDC) funded the
College of American Pathologists (CAP) as one of three professional
organizations in 5-year cooperative agreement projects collectively
entitled ``Improving the Impact of Laboratory Practice Guidelines: A
New Paradigm for Metrics.'' An ``LPG'' is defined as written
recommendations for voluntary, standardized approaches for medical
laboratory testing that takes into account processes for test
selection, sample procurement and processing, analytical methods, and
results reporting for effective diagnosis and management of disease and
health conditions. The overall purpose of these cooperative agreements
is to increase the effectiveness of LPGs by defining measures and
collecting information to inform better LPG creation, revision,
dissemination, promotion, uptake, and impact on clinical testing and
public health. The project will explore how these processes and their
impediments and facilitators differ among various intended users of
LPGs. Through this demonstration project, CDC seeks to understand how
to customize LPG creation and promotion to better serve these intended
users of LPGs. An important goal is to help organizations that sponsor
the development of LPGs create a sustainable approach for continuous
quality improvement to evaluate and improve an LPG's impact through
better collection of information.
One of the awardees is the College of American Pathologists (CAP).
This revision request concerns additional information collection
relating to the CAP's LPG for immunohistochemistry (IHC) testing, for
which a post dissemination survey was approved under OMB Control No.
0920-1067 and has been completed. We are requesting a revision to the
OMB-approved 0920-1067 package by adding two information collections:
Telephone interviews and focus groups as a follow-up to the completed
IHC LPG post survey to further explore the survey findings that are
being analyzed now. The questions to be used for the telephone
interviews and focus groups are based on the questions and results of
the IHC post survey, to help CAP and CDC better understand the
impediments and facilitators that affect uptake of the IHC LPG. The
intended participants in the proposed telephone interviews and focus
groups will be selected from the IHC post survey respondents which
include pathologists, pathology chairs, clinical laboratory directors,
laboratory managers overseeing the IHC staining department, laboratory
supervisors, and histotechnologists.
This revision request represents a decrease in burden. The proposed
telephone interviews will explore the impediments and facilitators that
affect uptake and use of the CAP IHC LPG, both generally and concerning
specific recommendations. This will be followed by two focus groups,
arranged into two peer groups of pathologists (composed of
pathologists, pathology chairs, and laboratory directors) and non-
pathologist laboratory professionals (composed of laboratory managers,
laboratory supervisors, and histotechnologists for the purpose of
estimating burden), which will allow us to collect information on the
current usage of CAP's tools and resources (toolkit) to facilitate
implementation of the IHC guideline for its future improvement.
For this request, the CAP will collect information via 40 telephone
interviews (20 pathologists, 10 laboratory directors, and 10 laboratory
managers). The telephone interview questions are scripted to be
completed within 20 minutes by each respondent (0.33 hour per
respondent or ~13 hours total). Because the CAP anticipates that
approximately 121 laboratory individuals (41 pathologists, 40
laboratory directors, and 40 laboratory managers) will need to be
contacted to reach 40 individuals who will voluntarily participate, and
the burden for those individuals who will not go on to participate (81)
in the telephone interview is one minute, the total burden for
individuals who decline participation is 81 minutes (1.35 hours).
In addition, the CAP will conduct two focus group sessions and
invite 12 participants to each of the sessions, composed of the
following respondent types: (4) Pathologists, (4) pathology chairs, (4)
laboratory directors, (4) laboratory managers, (4) laboratory
supervisors, and (4) histotechnologists. Each of the focus groups will
last no more than 60 minutes (1.0 hour) which is based on standard
focus group planning instructions, inclusive of time required to
complete informed consent (24 hours or 1,440 minutes total burden). It
is anticipated that 200 individuals will be contacted to determine
their availability to participate in one of the two focus group
sessions and each will take no longer than 5 minutes to read and
respond to the invitation letter (~17 hours or 1000 minutes total). The
200 individuals contacted will be composed of the following respondent
types: (34) Pathologists, (33) pathology chairs, (33) laboratory
directors, (34) laboratory managers, (33) laboratory supervisors, and
(33) histotechnologists.
This revision includes three types of laboratory professionals who
were not included in the original OMB-approved submission: Pathology
chairs, laboratory supervisors, and histotechnologists. Because the
OMB-approved IHC post-survey has been completed, this request for
approval of additional data collection (telephone interviews and focus
groups) is a reduction of burden. The total new burden for this
revision request will be ~58 hours which is a reduction of 1,512 hours
from the previously approved submission. A total of 321 respondents
(121 invited to take the telephone interview and 200 invited to
participate in focus groups), is a reduction of 4,114 respondents with
an approved burden of 1,570 hours and 4,435 respondents).
There are no costs to respondents other than their time.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Form name Type of respondent Number of responses per per response
respondents respondent (in hours)
----------------------------------------------------------------------------------------------------------------
IHC telephone interview-contacted..... Pathologists............ 41 1 1/60
Laboratory Directors.... 40
Laboratory Managers..... 40
IHC telephone interview............... Pathologists............ 20 1 20/60
Laboratory Directors.... 10
Laboratory Managers..... 10
IHC focus group invitation............ Pathologists............ 34 1 5/60
[[Page 23299]]
Pathology Chairs........ 33
Laboratory Directors.... 33
Laboratory Managers..... 34
Laboratory Supervisors.. 33
Histotechnologists...... 33
IHC focus group....................... Pathologists............ 4 1 1
Pathology Chairs........ 4
Laboratory Directors.... 4
Laboratory Managers..... 4
Laboratory Supervisors.. 4
Histotechnologists...... 4
----------------------------------------------------------------------------------------------------------------
LeRoy A. Richardson,
Chief, Information Collection Review Office, Office of Scientific
Integrity, Office of the Associate Director for Science, Office of the
Director, Centers for Disease Control and Prevention.
[FR Doc. 2016-09190 Filed 4-19-16; 8:45 am]
BILLING CODE 4163-18-P